Last updated on June 2018

Study for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients


Brief description of study

The purpose of this study is to compare the efficacy and safety of maribavir to valganciclovir for the treatment of cytomegalovirus (CMV) infection in asymptomatic hematopoietic stem cell transplant recipients.

Clinical Study Identifier: NCT02927067

Contact Investigators or Research Sites near you

Start Over

Eric Deconinck, MD, PhD

Hopital Jean Minjoz
Besnçon, France
  Connect »